MIP-1 alpha and myeloma bone disease.

Abstract

Figure 5 is a proposed model for MIP-1alpha's effects on myeloma bone disease. MIP-1alpha is produced by myeloma cells and directly stimulates OCL formation. In addition MIP-1alpha enhances adhesive interactions between myeloma cells and marrow stromal cells increasing expression of RANKL and IL-6, which further increase bone destruction and tumor burden. The recent evidence from our group and others lead to the conclusion that MIP-1alpha is an important mediator in the debilitating bone destruction in multiple myeloma. Blocking MIP-1alpha expression may have profound effects on myeloma cell growth, homing, and bone destruction in this in vivo model of myeloma. These data suggest that antagonists that decrease MIP-1alpha activity in vivo or blocking MIP-1alpha signaling by neutralizing its receptor may provide therapeutic alternatives for treating patients with myeloma to decrease both their tumor burden and bone destruction.

• Authors: G David Roodman, Sun Jin Choi
• Journal: Cancer treatment and research (Cancer Treat Res) Vol. 118 Pg. 83-100 ( 2004) ISSN: 0927-3042 [Print] United States
• PMID: 15043189 (Publication Type: Journal Article, Review)

Chemical References

• Biomarkers, Tumor
• Chemokine CCL3
• Chemokine CCL4
• Lymphokines
• Macrophage Inflammatory Proteins
• osteoclast activating factor

Topics

• Animals
• Biomarkers, Tumor (metabolism)
• Bone Diseases (pathology)
• Chemokine CCL3
• Chemokine CCL4
• Humans
• Lymphokines (metabolism)
• Macrophage Inflammatory Proteins (metabolism)
• Models, Biological
• Multiple Myeloma (metabolism)
• Osteoclasts (physiology)
• Prognosis